Patents by Inventor Min Ge
Min Ge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11525142Abstract: The present invention clones a gene ZmNLP5 from maize, which plays an important regulatory role in nitrogen assimilation, and the open reading frame of which has a DNA sequence shown as SEQ ID NO:1. The transcription factor protein encoded by the ZmNLP5 gene has an amino acid sequence shown as SEQ ID NO:2. The uses of the maize NLP transcription factor ZmNLP5 mentioned above in promoting expression of a nitrogen metabolic key enzyme gene ZmNIR1.1, in promoting expression of a nitrogen metabolic key enzyme gene ZmNIR1.2, in promoting expression of a nitrogen metabolic key enzyme gene ZmNR1.1, in promoting expression of a nitrogen metabolic key enzyme gene ZmNR1.2, in improving nitrogen assimilation in maize, and in promoting elongation growth of maize root in deficient nitrogen environment are further provided.Type: GrantFiled: July 21, 2020Date of Patent: December 13, 2022Assignee: JIANGSU ACADEMY OF AGRICULTURAL SCIENCESInventors: Min Ge, Yuancong Wang, Yuhe Liu, Han Zhao
-
Publication number: 20200347398Abstract: The present invention clones a gene ZmNLP5 from maize, which plays an important regulatory role in nitrogen assimilation, and the open reading frame of which has a DNA sequence shown as SEQ ID NO:1. The transcription factor protein encoded by the ZmNLP5 gene has an amino acid sequence shown as SEQ ID NO:2. The uses of the maize NLP transcription factor ZmNLP5 mentioned above in promoting expression of a nitrogen metabolic key enzyme gene ZmNIR1.1, in promoting expression of a nitrogen metabolic key enzyme gene ZmNIR1.2, in promoting expression of a nitrogen metabolic key enzyme gene ZmNR1.1, in promoting expression of a nitrogen metabolic key enzyme gene ZmNR1.2, in improving nitrogen assimilation in maize, and in promoting elongation growth of maize root in deficient nitrogen environment are further provided.Type: ApplicationFiled: July 21, 2020Publication date: November 5, 2020Inventors: Min GE, Yuancong WANG, Yuhe LIU, Han ZHAO
-
Patent number: 9828413Abstract: The present invention provides a vancomycin derivative, and a preparation method and an application thereof. The vancomycin derivative of the present invention is obtained by introducing a glycerate moiety between a vancomycin derivative and a liposoluble modification group and has reduced liposolubility and improved water solubility, thereby reducing a side effect in the cardiovascular aspect.Type: GrantFiled: April 22, 2014Date of Patent: November 28, 2017Assignee: ACESYS PHARMA INC.Inventor: Min Ge
-
Publication number: 20170088674Abstract: The present invention discloses a polymetallocarbosilane from organic metal catalysed polymerization and uses thereof, said polymetallocarbosilane has a structural formula as shown in (I). In the formula, R is methyl, ethyl, propyl, ethenyl, chloromethyl, phenyl or phenethyl; M is Ti, Zr or Hf; m is an integer equal to or greater than 1, n is an integer equal to or greater than 0, and Cp1 and Cp2 are each a cyclopentadienyl or substituted cyclopentadienyl group. The present invention adopts a method for producing polymetallocarbosilane by metallocene catalysed addition polymerization of an organosilane, with adjustability of metal content in polymer, simple reaction steps, mild reaction conditions and low preparation costs.Type: ApplicationFiled: July 30, 2015Publication date: March 30, 2017Inventors: Weigang ZHANG, Min GE, Yuelong TIAN, Shouquan YU, Xiaoxu LV
-
Publication number: 20160200768Abstract: The present invention provides a vancomycin derivative, and a preparation method and an application thereof. The vancomycin derivative of the present invention is obtained by introducing a glycerate moiety between a vancomycin derivative and a liposoluble modification group and has reduced liposolubility and improved water solubility, thereby reducing a side effect in the cardiovascular aspect.Type: ApplicationFiled: April 22, 2014Publication date: July 14, 2016Inventor: Min GE
-
Patent number: 8039484Abstract: Diaryl ethers in which one of the aryl groups is a phenyl fused to a cycloalkyl or heterocyclic ring, to which is attached an acetic acid group, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that often accompany this disease, including insulin resistance, obesity and lipid disorders.Type: GrantFiled: October 26, 2007Date of Patent: October 18, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: Min Ge, Songnian Lin, Shawn P. Walsh, Lihu Yang, Changyou Zhou
-
Patent number: 7759493Abstract: Bicyclic compounds containing a phenyl or pyridyl ring fused to a cycloalkyl or heterocyclic ring, to which is attached a 5-membered heterocyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.Type: GrantFiled: January 30, 2006Date of Patent: July 20, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Min Ge, Lihu Yang, Changyou Zhou, Songnian Lin, Haifeng Tang, Eric Dean Cline, Sunita Malkani
-
Publication number: 20100105725Abstract: Diaryl ethers in which one of the aryl groups is a phenyl fused to a cycloalkyl or heterocyclic ring, to which is attached an acetic acid group, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that often accompany this disease, including insulin resistance, obesity and lipid disorders.Type: ApplicationFiled: October 26, 2007Publication date: April 29, 2010Inventors: Min Ge, Songnian Lin, Shawn P. Walsh, Lihu Yang, Changyou Zhou
-
Publication number: 20090312303Abstract: Bicyclic compounds containing a phenyl or pyridyl ring fused to a cycloalkyl or heterocyclic ring, to which is attached a 5-membered heterocyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.Type: ApplicationFiled: January 30, 2006Publication date: December 17, 2009Applicant: MERCK & CO., INC.Inventors: Min Ge, Lihu Yang, Changyou Zhou, Songnian Lin, Haifeng Tang, Eric Dean Cline, Sunita Malkani
-
Publication number: 20090253673Abstract: Certain novel N-acylated spiropiperidine derivatives are ligands of the human ghrelin receptor(s) and, in particular, are antagonists/inverse agonists of the human ghrelin receptor. They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of the ghrelin receptor, such as obesity, diabetes, and metabolic syndrome.Type: ApplicationFiled: July 6, 2007Publication date: October 8, 2009Inventors: Min Ge, Eric Cline, Lihu Yang, Sander G. Mills
-
Patent number: 7473671Abstract: A glycopeptide of the formula A1-A2-A3-A4-A5-A6-A7, in which each dash represents a covalent bond; wherein A1 comprises a modified or unmodified ?-amino acid residue, alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocyclic, heterocyclic-carbonyl, heterocyclic-alkyl, heterocyclic-alkyl-carbonyl, alkylsulfonyl, arylsulfonyl, guanidinyl, carbamoyl, or xanthyl; wherein each of A2 to A7 comprises a modified or unmodified ?-amino acid residue, whereby (i) A1 is linked to an amino group on A2, (ii) each of A2, A4 and A6 bears an aromatic side chain, which aromatic side chains are cross-linked together by two or more covalent bonds, and (iii) A7 bears a terminal carboxyl, ester, amide, or N-substituted amide group; and wherein one or more of A1 to A7 is linked via a glycosidic bond to one or more glycosidic groups each having one or more sugar residues, at least one of the sugar residues bearing one or more substituents of the formula YXR, N+(R1)=CR2R3, N=PR1R2R3, N+R1R2R3 or P+R1R2R3 in which Y is a singlType: GrantFiled: July 31, 2003Date of Patent: January 6, 2009Assignee: The Trustees of Princeton UniversityInventors: Daniel Kahne, Robert Kerns, Seketsu Fukuzawa, Min Ge, Christopher Thompson
-
Patent number: 7442808Abstract: Tricyclic compounds containing a cyclopropyl carboxylic acid or carboxylic acid derivative (e.g. amide) fused to a bicyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.Type: GrantFiled: May 11, 2007Date of Patent: October 28, 2008Assignee: Merck & Co., Inc.Inventors: Min Ge, Jiafang He, Fiona Wai Yu Lau, Gui-Bai Liang, Songnian Lin, Weiguo Liu, Shawn P. Walsh, Lihu Yang
-
Patent number: 7361765Abstract: The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro-2H-pyran-4-yl]amine and its succinate salt. The present invention additionally provides an efficient syntheses for the preparation of intermediates (3R)-3-methoxytetrahydro-4H-pyran-4-one; (1S,4S)-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1-isopropylcyclopent-2-ene-1-carboxylic acid; and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine; and for the preparation of the precursor (3S,4S)-N-((1S,4S)-4-isopropyl-4-{[3-(tri-fluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopent-2-en-1-yl)-3-methoxytetrahydro-2H-pyran-4-amine.Type: GrantFiled: October 25, 2004Date of Patent: April 22, 2008Assignee: Merck & Co., Inc.Inventors: Dongwei Cai, Fred Fleitz, Min Ge, Scott Hoerrner, Gary Javadi, Mark Jensen, Robert Larsen, Wenjie Li, Dorian Nelson, Elizabeth Szumigala, Lihu Yang, Changyou Zhou
-
Publication number: 20080090865Abstract: Bicyclic compounds containing a fused pyridine ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.Type: ApplicationFiled: January 24, 2006Publication date: April 17, 2008Inventors: Min Ge, Lihu Yang, Changyou Zhou, Songnian Lin, Eric Cline
-
Patent number: 7331920Abstract: Methods for preparing a glycopeptide are disclosed. The methods comprise the steps of selecting a protected glycopeptide of the formula A1-A2-A3-A4-A5-A6-A7, wherein the groups A1 to A7 comprise the heptapeptide structure of naturally occurring vancomycin; at least A4 is linked to a glycosidic group which has a hexose residue linked to A4; and the protected glycopeptide has no free amino or carboxyl groups and has a free primary hydroxyl group only at the 6-position of said hexose residue. The protected glycopeptide is contacted with a compound of the formula ArSO2G where Ar is an aryl group and G is a leaving group under conditions effective to allow reaction of said free primary hydroxyl group to form a glycopeptide sulfonate ester; and the glycopeptide sulfonate ester is contacted with a nucleophile under conditions effective to allow displacement of a sulfonate group to produce a substituted glycopeptide.Type: GrantFiled: October 1, 2003Date of Patent: February 19, 2008Assignee: The Trustees of Princeton UniversityInventors: Daniel Kahne, Robert Kerns, Seketsu Fukuzawa, Min Ge, Christopher Thompson
-
Publication number: 20070265332Abstract: Tricyclic compounds containing a cyclopropyl carboxylic acid or carboxylic acid derivative (e.g. amide) fused to a bicyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.Type: ApplicationFiled: May 11, 2007Publication date: November 15, 2007Inventors: Min Ge, Jiafang He, Fiona Wai Yu Lau, Gui-Bai Liang, Songnian Lin, Weiguo Liu, Shawn P. Walsh, Lihu Yang
-
Publication number: 20070135475Abstract: The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro-2H-pyran-4-yl]amine and its succinate salt. The present invention additionally provides an efficient syntheses for the preparation of intermediates (3R)-3-methoxytetrahydro-4H-pyran-4-one; (1S,4S)-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1-isopropylcyclopent-2-ene-1-carboxylic acid; and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine; and for the preparation of the precursor (3S,4S)-N-((1S,4S)-4-isopropyl-4-{[3-(tri-fluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopent-2-en-1-yl)-3-methoxytetrahydro-2H-pyran-4-amine. The invention additionally resides in the superior properties of the succinate salt of ((1R,3S)-3-isopropyl-3-1{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine.Type: ApplicationFiled: October 25, 2004Publication date: June 14, 2007Inventors: Dongwei Cai, Fred Fleitz, Min Ge, Scott Hoerner, Gary Javadi, Mark Jensen, Robert Larsen, Wenjie Lie, Dorian Nelson, Elizabeth Szumigala, Lihu Yang, Changyou Zhou
-
Publication number: 20060183731Abstract: The present invention is directed to compounds of the formula: wherein R1, R1, R3, R4, R5, R6, R7, R8, R9, R10 and R16 are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.Type: ApplicationFiled: July 9, 2004Publication date: August 17, 2006Inventors: Min Ge, Stephen Goble, Alexander Pasternak, Lihu Yang
-
Publication number: 20050075483Abstract: A glycopeptide of the formula A1-A2-A3-A4-A5-A6-A7, in which each dash represents a covalent bond; wherein A1 comprises a modified or unmodified ?-amino acid residue, alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocyclic, heterocyclic-carbonyl, heterocyclic-alkyl, heterocyclic-alkyl-carbonyl, alkylsulfonyl, arylsulfonyl, guanidinyl, carbamoyl, or xanthyl; wherein each of A2 to A7 comprises a modified or unmodified ?-amino acid residue, whereby (i) A1 is linked to an amino group on A2, (ii) each of A2, A4 and A6 bears an aromatic side chain, which aromatic side chains are cross-linked together by two or more covalent bonds, and (iii) A7 bears a terminal carboxyl, ester, amide, or N-substituted amide group; and wherein one or more of A1 to A7 is linked via a glycosidic bond to one or more glycosidic groups each having one or more sugar residues, at least one of the sugar residues bearing one or more substituents of the formula YXR, N+(R1)?CR2R3, N?PR1R2R3, N+R1R2R3 or P+R1R2R3 in which Y is a singleType: ApplicationFiled: October 1, 2003Publication date: April 7, 2005Inventors: Daniel Kahne, Robert Kerns, Seketsu Fukuzawa, Min Ge, Christopher Thompson
-
Publication number: 20040180813Abstract: General methods for monitoring the activity of MurG, a GlcNAc transferase involved in bacterial cell wall biosynthesis, is disclosed. More particularly, the synthesis of simplified substrate analogs of Lipid I (the natural substrate for MurG), which function as acceptors for UDP-GlcNAc in an enzymatic reaction catalyzed by MurG, is described. Assays using the substrate analogs of the invention are further disclosed, which are useful for identifying a variety of other substrates, including inhibitors of MurG activity, for facilitating mechanistic and/or structural studies of the enzyme and for other uses. High throughput assays are also described.Type: ApplicationFiled: March 9, 2004Publication date: September 16, 2004Applicant: The Trustees Of Princeton UniversityInventors: Suzanne Walker Kahne, Hongbin Men, Peter Park, Min Ge